333954-86-2

Usage

Uses

Used in Pharmaceutical Research and Drug Discovery:
Tert-Butyl 4-(4-cyanophenoxy)piperidine-1-carboxylate is employed as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structural features, including the presence of a tert-butyl group, a cyanophenoxy group, and a carboxylate group, contribute to its potential as a building block in the creation of new medications.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, tert-Butyl 4-(4-cyanophenoxy)piperidine-1-carboxylate is used as a key component in the design and synthesis of bioactive molecules. Its structural diversity allows for the exploration of different chemical modifications, which can lead to the discovery of compounds with improved pharmacological properties, such as enhanced potency, selectivity, and reduced side effects.
Used in Drug Development:
Tert-Butyl 4-(4-cyanophenoxy)piperidine-1-carboxylate is utilized in the drug development process as a precursor for the production of potential therapeutic agents. Its involvement in this process may include the optimization of drug candidates, assessment of their pharmacokinetic and pharmacodynamic profiles, and evaluation of their safety and efficacy in preclinical and clinical studies.
Used in Chemical Synthesis:
In the realm of chemical synthesis, tert-Butyl 4-(4-cyanophenoxy)piperidine-1-carboxylate serves as a versatile reagent for the preparation of a wide range of organic compounds. Its functional groups can participate in various chemical reactions, such as nucleophilic substitution, esterification, and amide formation, enabling the synthesis of diverse chemical entities with potential applications in various industries, including pharmaceuticals, agrochemicals, and materials science.
Overall, the applications of tert-Butyl 4-(4-cyanophenoxy)piperidine-1-carboxylate are primarily centered around its role in the pharmaceutical and chemical industries, where its unique structural features and synthetic versatility contribute to the advancement of drug discovery and the development of novel chemical compounds.

Upstream product

• 623-03-0 4-Cyanochlorobenzene 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 767-00-0 4-cyanophenol 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 1194-02-1 4-fluorobenzonitrile 
• 118811-07-7 tert-butyl 4-(tosyloxy)piperidin-1-carboxylate 

Downstream Products

• 397275-27-3 4-((1-cyclobutylpiperidin-4-yl)oxy)benzonitrile 
• 1394808-23-1 N-[4-(1-cyclobutylpiperidin-4-yloxy)benzyl]morpholine-4-ylamide 
• 1394808-77-5 4-(1-cyclobutyl piperidin-4-yloxy)benzylamine 
• 769119-29-1 4-((1-cyclobutylpiperidin-4-yl)oxy)benzoic acid 
• 1087161-30-5 methyl 4-((1-cyclobutylpiperidin-4-yl)oxy)benzoate 
• 870997-68-5 4-((1-cyclobutylpiperidin-4-yl)oxy)benzaldehyde 
• 685565-27-9 4-[(1-cyclobutyl-4-piperidinyl)oxy]benzoic acid hydrochloride 
• 685565-28-0 4-[(1-cyclobutyl-4-piperidinyl)oxy]benzoyl chloride hydrochloride 
• 685565-69-9 N-{4-[(1-cyclobutyl-4-piperidinyl)oxy]benzoyl}-5-fluoroisoindoline 
• 685565-68-8 N-{4-[(1-cyclobutyl-4-piperidinyl)oxy]benzoyl}isoindoline 
• 528861-47-4 tert-butyl 4-[4-(1H-tetrazol-5-yl)phenoxy]-1-piperidinecarboxylate 
• 685565-26-8 4-(4-piperidinyloxy)benzonitrile trifluoroacetate 
• 397277-60-0 4-((1-benzylpiperidin-4-yl)oxy)benzonitrile 

Relevant academic research and scientific papers

NOVEL OXADIAZOLES

The present invention relates to novel compound of Formula I, wherein, R1, A1, A2, A3, A4, A5, L1, A, L2 and R2 are as defined in the detailed description. The present invention also relates to a combination or a composition comprising the compound of Formula I.

Tankyrase inhibitor

The invention belongs to the technical field of medicines and particularly relates to a tankyrase inhibitor represented by a general formula (I) shown in the description and pharmaceutically acceptable salts, esters, solvates or stereoisomers thereof, wherein R1, R2, R3, m, n, Z, L, Q, A, X1, X2 and Y are as defined in the description. The invention further relates to a preparation method for the compounds, pharmaceutical preparations and pharmaceutical compositions containing the compounds and application of the compound and the pharmaceutically acceptable salts, esters, solvates or stereoisomers thereof in preparation of drugs for treating and/or preventing tankyrase mediated cancers and related diseases.

MULTIPLE D2 A(NTA)GONISTS/H3 ANTAGONISTS FOR TREATMENT OF CNS-RELATED DISORDERS

The present invention relates to compounds compound according to Formula (III); and pharmaceutically acceptable salts, hydrates and solvates thereof. These compounds have D2receptor antagonist/(partial) agonist effects and H3antagonistic effects, pharmaceutical compositions thereof, and methods of using them for application in the prophylaxis or treatment of CNS disorders.

NOVEL COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS

The present invention relates to novel compounds of formula (I), and their pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their pha

NOVEL COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS

The present invention relates to novel compounds of formula (I), and their pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their pha

HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE

The present invention provides a novel hydroxyquinoxaline carboxamide derivative that is useful for preventing and/or treating blood coagulation disorders. A compound represented by formula (i), or a pharmacologically acceptable salt thereof: wherein, each of R1 and R2 independently represents a group such as a hydrogen atom or a halogen atom; R3 represents a group such as a hydrogen atom; each of R4 and R5 independently represents a group such as a hydrogen atom, a halogen atom or a C1-4 alkyl group; each of R6 and R7 independently represents a hydrogen atom or a C1-4 alkyl group; X represents a group such as a C3-10 cycloalkyl group, C6-10 aryl group or a 5- to 10-membered heterocyclic group, which may be substituted with substituent(s) selected from substituent group α; Y represents a group such as -CO-, -O- or -NRa-, and Ra represents a group such as a hydrogen atom or a C1-4 alkyl group.

SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHODS OF USING SAME

Disclosed are compounds active against soluble epoxide hydrolase (sEH), compositions thereof and methods of using and making same.

SELECTIVE ESTROGEN RECEPTOR MODULATORS

The present invention provides a compound represented by the following formula (I); [wherein T represents a single bond, a C1-C4 alkylene group which may have a substituent and the like; formula (I-1) represents a single bond or a double bond; A represents a single bond, a bivalent 5- to 14-membered heterocyclic group which may have a substituent and the like; Y represents a single bond and the like; Z represents a methylene group and the like; ring G represents a phenylene group and the like which may condense with a 5- to 6-membered ring and may have a heteroatom; Ra and Rb are the same as or different from each other and represent a hydrogen atom and the like; W represents a single bond and the like; R' represents 1 to 4 independent hydrogen atoms and the like; and R" represents 1 to 4 independent hydrogen atoms and the like] or a salt thereof, or a hydrate thereof.

OPIOID RECEPTOR ANTAGONISTS

A compound of the formula (I) wherein the variables X1 to X5, R1 to R7 including R3', E, q, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, dia

4-Phenoxypiperidines: Potent, conformationally restricted, non-imidazole histamine H3 antagonists

Two new series of 4-(1-alkyl-piperidin-4-yloxy)-benzonitriles and 4-(1-isopropyl-piperidin-4-yloxy)-benzylamines have been prepared. In vitro activity was determined at the recombinant human H3 receptor and several members of these new series were found to be potent H3 antagonists. The present compounds contain a 4-phenoxypiperidine core, which behaves as a conformationally restricted version of the 3-amino-1-propanol moiety common to the many previously described non-imidazole histamine H 3 ligands. One selected member of the new series, 4-[4-(1-isopropyl-piperidin-4-yloxy)-benzyl]-morpholine (13g), was found to be a potent, highly selective H3 receptor antagonist with in vivo efficacy in a rat EEG model of wakefulness at doses as low as 1 mg/kg sc.